Skip to main content
SpringerLink
Log in

Systemic Treatment of Small Cell Lung Cancer

  • Review Article
  • Published:
American Journal of Cancer

Abstract

Small cell lung cancer (SCLC) accounts for 20–25% of all lung cancer and is characterized by an aggressive clinical course with early dissemination and extremely high risk of recurrence. Chemotherapy has been the cornerstone of treatment, with high response rates including complete responses. Despite the sensitivity of this disease to cytotoxic drugs, the majority of patients will face recurrence and die of the disease within two years.

For more than thirty years, investigators have conducted numerous trials using different drug regimens and schedules, as well as different therapeutic modalities. The combination of cyclophosphamide, doxorubicin (adriamycin) and vincristine (CAV) was one of the first widely accepted regimens for the treatment of SCLC. Later, CAV and its hybrids were replaced by the similarly effective but less toxic regimen of cisplatin and etoposide (PE). Clinical investigators have tried different approaches to improve the efficacy of these regimens, such as alternating CAV/PE; consolidation and maintenance therapy; intensive treatment with high-dose chemotherapy; increased frequency of drug administration; or high dose therapy with stem cell support — all with no definitive successes, leaving PE as the standard treatment for patients with SCLC. The recent arrival of new chemotherapy agents such as topotecan, irinotecan, and taxanes may represent a step forward in the treatment of this disease. The most promising regimen is the combination of irinotecan and cisplatin which, according to Japanese investigators, achieves a significantly better survival than standard PE. If validated by confirmatory trials, this combination could well become the new standard treatment for extensive chemotherapy-naïve SCLC.

Biological agents are also being widely investigated, including vaccines, matrix metalloproteinase inhibitors, anti-sense therapy, and monoclonal antibodies. Advances in molecular biology will hopefully contribute to progress in the treatment of this lethal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Ihde D, Pass H, Glatstein EJ. Small cell lung cancer. In: DeVita V, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia (PA): Lippincott-Raven Publishers, 1997: 911–49

    Google Scholar 

  2. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93: 300–8

    Article  PubMed  CAS  Google Scholar 

  3. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593, a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 2114–22

    PubMed  CAS  Google Scholar 

  4. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85–91

    Article  PubMed  CAS  Google Scholar 

  5. Roth B, Johnson D, Einhorn L, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the southeastern cancer study group. J Clin Oncol 1992; 10: 282–91

    PubMed  CAS  Google Scholar 

  6. Livingston RB, Moore TN, Heilbrun L, et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med 1978; 88: 194–9

    PubMed  CAS  Google Scholar 

  7. Greco FA, Richardson RL, Snell JD, et al. Small cell lung cancer: complete remission and improved survival. Am J Med 1979; 66: 625–30

    Article  PubMed  CAS  Google Scholar 

  8. Feld R, Evans W, DeBoer G, et al. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 1984; 2: 294–304

    PubMed  CAS  Google Scholar 

  9. Grant SC, Gralla RJ, Kris MG, et al. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 1992; 10: 484–98

    PubMed  CAS  Google Scholar 

  10. Jackson DV, Zekan PJ, Caldwell RD, et al. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association. J Clin Oncol 1984; 2: 1343–51

    PubMed  Google Scholar 

  11. Jackson DV, Case LD, Zekan PJ, et al. Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 1988; 6: 1161–9

    PubMed  Google Scholar 

  12. Messeih AA, Schweitzer JM, Lipton A, et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 1987; 71: 61–6

    PubMed  CAS  Google Scholar 

  13. Einhorn L, Greco A, Wampler G, et al. Cytoxan (C), Adriamycin (A), Etoposide (E), versus Cytoxan, Adriamycin, Vincristine (V) in the treatment of small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1987; 6: 168

    Google Scholar 

  14. Schabel F, Trader M, Laster W, et al. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459–73

    PubMed  CAS  Google Scholar 

  15. Aisner J, Abrams J. Cisplatin for small-cell lung cancer. Semin Oncol 1989; 16: 2–9

    PubMed  CAS  Google Scholar 

  16. Evans W, Shepherd F, Feld R, et al. VP-16 and Cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985; 3: 1471–7

    PubMed  CAS  Google Scholar 

  17. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristin versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855–61

    Article  PubMed  CAS  Google Scholar 

  18. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987; 5: 1574–8

    PubMed  CAS  Google Scholar 

  19. Evans WK, Eisenhauer E, Hughes P, et al. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer 1988; 58: 464–8

    Article  PubMed  CAS  Google Scholar 

  20. Skarlos D, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 1994; 5: 601–7

    PubMed  CAS  Google Scholar 

  21. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–33

    PubMed  CAS  Google Scholar 

  22. Goodman G, Crowley J, Blasko J, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group study. J Clin Oncol 1990; 8: 39–47

    PubMed  CAS  Google Scholar 

  23. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987; 107: 451–8

    PubMed  CAS  Google Scholar 

  24. Wampler GL, Heim WJ, Ellison NM, et al. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1991; 9: 1438–45

    PubMed  CAS  Google Scholar 

  25. Einhorn L, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following Cyclophosphamide, Doxorubicin, and Vincristine in limited stage small-cell lung cancer. J Clin Oncol 1988; 6: 451–6

    PubMed  CAS  Google Scholar 

  26. Ettinger D, Finkelstein D, Abeloff M, et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase II study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990; 8: 230–40

    PubMed  CAS  Google Scholar 

  27. Spiro S, Souhami R, Geddes D, et al. Duration of chemotherapy in small cell lung cancer: a cancer research campaign trial. Br J Cancer 1989; 59: 578–83

    Article  PubMed  CAS  Google Scholar 

  28. Giaccone G, Dalesio O, Me Vie G, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 1993; 11: 1230–40

    PubMed  CAS  Google Scholar 

  29. Sculier JP, Berghman T, Castaigne C, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998; 19: 141–51

    Article  PubMed  CAS  Google Scholar 

  30. Figueredo T, Hryniuk W, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3: 54–64

    PubMed  CAS  Google Scholar 

  31. Johnson D, Einhorn L, Birch R, et al. A randomized comparison of high-dose vs conventional-dose cyclophosphamide, doxorubicin, and vincristine for expensive-stage small-cell lung cancer. J Clin Oncol 1987; 5: 1731–8

    PubMed  CAS  Google Scholar 

  32. Klasa R, Murray N, Coldman A. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9: 499–508

    PubMed  CAS  Google Scholar 

  33. Arriagada R, LeChevalier T, Pignon J-P, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329(25): 1848–52

    Article  PubMed  CAS  Google Scholar 

  34. Ihde D, Mulshine J, Kramer B, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12: 2022–34

    PubMed  CAS  Google Scholar 

  35. Murray N, Shah A, Osoba D, et al. Intensive weekly chemotherapy for the treatment of extensive stage small cell lung cancer. J Clin Oncol 1991; 9(9): 1632–8

    PubMed  CAS  Google Scholar 

  36. Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997; 75: 306–9

    Article  PubMed  CAS  Google Scholar 

  37. Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer: the Japan Clinical Oncology Group. J Clin Oncol 1998; 16: 2126–32

    PubMed  CAS  Google Scholar 

  38. Murray N, Livingston R, Shepherd F, et al. Randomized study of code versus alternating cav/ep for extensive-stage small-cell lung cancer: an Intergroup Study for the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17: 2300–8

    PubMed  CAS  Google Scholar 

  39. Lazarus H, Elias A. Autologous bone marrow and peripheral blood progenitor cell transplants in small cell lung cancer. Bone Marrow Transplant 1996; 17: 1–3

    PubMed  CAS  Google Scholar 

  40. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autolgous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864–73

    PubMed  CAS  Google Scholar 

  41. Humblet Y, Bosquee L, Weynants P. High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells. Bone Marrow Transplant 1996; 18: S36–9

    PubMed  Google Scholar 

  42. Elias A, Ibrahim J, Skarin AT, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999; 17: 1175

    PubMed  CAS  Google Scholar 

  43. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest 1999; 116: 531S–8S

    Article  PubMed  CAS  Google Scholar 

  44. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial (E1592). J Clin Oncol 1996; 14: 2345–52

    PubMed  CAS  Google Scholar 

  45. Nair S. A phase II study of paclitaxel and cisplatin in the treatment of extensive stage small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 454a

    Google Scholar 

  46. Thomas P. Phase II trial of paclitaxel and carboplatin in metastatic small cell lung cancer: a Group Francais de Pneumo-Cancerologie Study. J Clin Oncol 2001; 19: 1320–5

    PubMed  CAS  Google Scholar 

  47. Israel V, Chansky K, Gandara D. Southwest Oncology Group Trial S9718: a phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer [abstract]. Proc Am Soc Clin One 2001; 20: 316a

    Google Scholar 

  48. Perez-Soler R, Glisson B, Lee J, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14(10): 2785–90

    PubMed  CAS  Google Scholar 

  49. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15: 2090–6

    PubMed  CAS  Google Scholar 

  50. Eckardt J, Gralla R, Palmer MC, et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study [abstract]. Ann Oncol 1996; 7: 107

    Article  Google Scholar 

  51. von Pawel J, Schiller J, Sheperd F, et al. Topotecan versus CAV for the treatment of recurrent small cell lung cancer. J Clin Oncol 1999; 17: 658–67

    Google Scholar 

  52. Bertrand R, O’Connor R, Kerrigan D, et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon-carcioma HT-29 cells. Eur J Cancer 1992; 28A: 743–8

    Article  PubMed  CAS  Google Scholar 

  53. Anzi H, Frost P, Abbruzzese J. Synergistic cytoxicity with combined inhibition of topoisomerase I and II [abstract]. Proc Am Soc Clin One 1992; 33: 431

    Google Scholar 

  54. Kim R, Hirabayashi N, Nishiyama M, et al. Experimental studies on biochemical moduation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992; 50: 760–6

    Article  PubMed  CAS  Google Scholar 

  55. Bonner J, Kozelsky T. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 1996; 39(1-2): 109–12

    Article  PubMed  CAS  Google Scholar 

  56. Eckardt J. Oral topotecan as single-agent first-line treatment for patients with extensive disease small cell lung cancer ineligible for standard therapy [abstract]. Proc Am Soc Clin Oncol 2000; 19: 494a

    Google Scholar 

  57. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19: 1743–9

    Google Scholar 

  58. Lynch T, Herndon J, Lyss A, et al. Paclitaxel (P) + Topotecan (T) + GCSF (G) for previously untreated extensive stage small cell lung cancer (E-SCLC): preliminary analysis of cancer and leukemia group B (CALGB) 9430 [abstract]. Proc Am Soc Clin Oncol 2000; 19: 491a

    Google Scholar 

  59. Jacobs S, Jett J, Belani C, et al. Topotecan and Paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 470a

    Google Scholar 

  60. Gray J, Hainsworth JD, Burris H, et al. Paclitaxel, Carboplatin, and Topotecan in the treatment of small cell lung cancer: a phase II trial of the minnie pearl cancer research network [abstract]. Proc Am Soc Clin Oncol 2000; 19: 494a

    Google Scholar 

  61. Panza N, Frasci G, Cornelia P, et al. Weekly Cisplatin-Paclitaxel-Topotecan (CPT) as front-line therapy for extensive disease small cell lung cancer (ED-SCLC) [abstract]. Proc Am Soc Clin Oncol 2000; 19: 492a

    Google Scholar 

  62. Vassilis G, Veslemes M, Palamidas P, et al. A phase II study alternating cisplatin-etoposide and topotecan administration in patients with extensive stage small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 2001; 20: 318a

    Google Scholar 

  63. Felip E, Font A, Rosell R, et al. Preliminary results of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC): a phase II study [abstract]. Ann Oncol 2000; 11: 120

    Google Scholar 

  64. Jett J, Hatfield A, Bauman M, et al. Phase II trial of topotecan and paclitaxel (TP) with G-CSF support alternating with etoposide and cisplatin (EC) in previously untreated extensive stage small cell lung cancer (ED-SCLC) [abstract]. Proc Am Soc Clin Oncol 2000; 19: 491a

    Google Scholar 

  65. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer: CPT-11 Cooperative Study Group. Gan to Kagaku Ryoho 1991; 18: 1013–9

    PubMed  CAS  Google Scholar 

  66. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225–9

    PubMed  CAS  Google Scholar 

  67. Le Chevalier T, Ibrahim N, Chomy P, et al. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to firstline chemotherapy (CT) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 450a

    Google Scholar 

  68. Devore R, Blanke C, Denham C, et al. Phase II study of Irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1998; 17: 451a

    Google Scholar 

  69. Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer: West Japan Lung Cancer Group. J Clin Oncol 1998; 16: 1068–74

    PubMed  CAS  Google Scholar 

  70. Okishio K, Furuse M, Kawahara M, et al. A phase II study of Irinotecan (CPT-11) and Cisplatin (CDDP) in previously treated small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1998; 17: 497a

    Google Scholar 

  71. Ando M, Kobayashi K, Yoshioka H, et al. Weekly administration of Irinotecan (CPT-11) plus Cisplatin (CDDP) for refractory or relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 2001; 20: 319a

    Google Scholar 

  72. Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998; 16: 3329–34

    PubMed  CAS  Google Scholar 

  73. Fujita A, Takabatake H, Tagaki S, et al. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology 2000; 59: 105–9

    Article  PubMed  CAS  Google Scholar 

  74. Ettinger D, Finkelstein D, Sarma R, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1430–5

    PubMed  CAS  Google Scholar 

  75. Kirschling RJ, Jung SH, Jett JR. Group NCCT. A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 326

    Google Scholar 

  76. Gridelli C. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 2001; 84: 38–41

    Article  PubMed  CAS  Google Scholar 

  77. Kelly K. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res 1999; 5: 3419–24

    PubMed  CAS  Google Scholar 

  78. Glisson BS, Kurie JM, Perez-Soler R, et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 1999; 17: 2309–15

    PubMed  CAS  Google Scholar 

  79. Dowlati LC, Remick SC. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer: the use complete response rate as the primary endpoint in phase II trials. Lung Cancer 2001; 32: 155–62

    Article  PubMed  CAS  Google Scholar 

  80. Hainsworth J, Gray J, Stroup S. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997; 15: 3464–70

    PubMed  CAS  Google Scholar 

  81. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A: 1058–60

    Article  PubMed  CAS  Google Scholar 

  82. Nakamura H, Azuma M, Miyagi K. A pilot study of docetaxel as salvage chemotherapy in small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001; 20: 280b

    Google Scholar 

  83. Burris H, Crowley J, Williamson S. Docetaxel in extensive stage small cell lung cancer: a phase II trial of the Southwest Oncology Group [abstract]. Proc Am Soc Clin Oncol 1998; 17: 451a

    Google Scholar 

  84. Lianes P, Moreno-Nogueira J, Cardenal F. Multicenter phase II clinical trial of docetaxel in combination with cisplatin in first-line chemotherapy for small cell lung cancer extensive disease: final results [abstract]. Proc Am Soc Clin Oncol 2001; 20: 282b

    Google Scholar 

  85. Bahadori HR, Lima CM, Green MR, et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999; 19: 5423–8

    PubMed  CAS  Google Scholar 

  86. Kristjansen PEG, Quistorff B, Spang-Thomsen M, et al. Intratumoral pharmaco-kinetic analysis by 19f-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dfdc) in two small cell lung cancer xenografts. Ann Oncol 1993; 4: 157–60

    PubMed  CAS  Google Scholar 

  87. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (sclc), a study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 283–5

    PubMed  CAS  Google Scholar 

  88. Vansteenkiste J, Gatzemeier U, Manegold C. Gemcitabine plus etoposide in chemonaive extensive disease small cell lung cancer: a multi-centre phase II study. Ann Oncol 2001; 12: 835–40

    Article  PubMed  CAS  Google Scholar 

  89. Earle CC, Stewart DJ, Cormier Y, et al. A phase I study of gemcitabine/cisplatin/ etoposide in the treatment of small-cell lung cancer. Lung Cancer 1998; 22: 235–41

    Article  PubMed  CAS  Google Scholar 

  90. Steele J. Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation. Semin Oncol 2001; 28: 15–8

    Article  PubMed  CAS  Google Scholar 

  91. Harper P, Underhill C, Ruiz de Elvira MC, et al. A randomised study of oral etoposide versus combination chemotherapy in poor prognosis small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1996; 15: 2019

    Google Scholar 

  92. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell cancer: a stopped multicentre randomized trial. Lancet 1996; 348: 563–6

    Article  Google Scholar 

  93. Grant SC, Kris MG, Houghton AN, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999; 5: 1319–23

    PubMed  CAS  Google Scholar 

  94. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489–97

    Article  PubMed  CAS  Google Scholar 

  95. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996; 334: 316–8

    Article  PubMed  CAS  Google Scholar 

  96. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–6

    Article  PubMed  CAS  Google Scholar 

  97. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407–11

    PubMed  CAS  Google Scholar 

  98. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodg-kin’s lymphoma. J Clin Oncol 2000; 18: 1812–23

    PubMed  CAS  Google Scholar 

  99. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728–33

    Article  PubMed  CAS  Google Scholar 

  100. Morris M, Tong W, Osman I, et al. A phase I/IIA dose-escalating trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies. Proc Am Soc Clin Oncol 1999; 18: 323a

    Google Scholar 

  101. Rudin C, Otterson C, George M, et al. A phase I/II trial of genasense and paclitaxel in chemorefractory small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001; 20: 322a

    Google Scholar 

  102. Parsons S, Watson S, Brown P, et al. Matrix metalloproteinases. Br J Surg 1997; 84: 160–6

    Article  PubMed  CAS  Google Scholar 

  103. Stetler-Stevenson W, Hewitt H, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147–54

    Article  PubMed  CAS  Google Scholar 

  104. Chambers A, Matrisian L. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260–70

    Article  PubMed  CAS  Google Scholar 

  105. Urbanski S, Edwards D, Maitland A, et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66: 1188–94

    Article  PubMed  CAS  Google Scholar 

  106. Kossakowska A, Huchcroft S, Urbanski S, et al. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer 1996; 73: 1401–8

    Article  PubMed  CAS  Google Scholar 

  107. Canete-Soler R, Litzky L, Lubensky I, et al. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol 1994; 144: 518–27

    PubMed  CAS  Google Scholar 

  108. Brown P, Bloxidge R, Stuart N, et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 574–8

    Article  PubMed  CAS  Google Scholar 

  109. Clarke M, Landreneau R, Finkelstein S, et al. Extracellular matrix expression in metastasizing and nonmetastasizing adenocaracinomas of the lung. Hum Pathol 1997; 28: 54–9

    Article  PubMed  CAS  Google Scholar 

  110. Anderson I, Shipp M, Docherty A, et al. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996; 56: 715–8

    CAS  Google Scholar 

  111. Nelson A, Fingleton B, Rothenberg M, et al. Matrix Metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135

    PubMed  CAS  Google Scholar 

  112. Bayer halts clinical trials evaluating MMPI [press release]. Bayer Healthcare. Available from URL: http://www.bayerpharma-na.com/news/co0221.aspIAccessed 1999 Sep 9]

  113. Shepherd F, Giaccone G, Debruyne C, et al. Randomized double-blind placebo controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC Study. Proc Am Soc Clin Oncol 2001; 20: 4a

    Google Scholar 

  114. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 307a

    Google Scholar 

  115. Chaudhry A, Carrasquillo JA, Avis IL, et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 1999; 5: 3385–93

    PubMed  CAS  Google Scholar 

  116. Mattson K, Niiranen A, Ruotsalainen T, et al. Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. J Interferon Cytok-ine Res 1997; 17: 103–5

    Article  CAS  Google Scholar 

  117. Kelly K, Crowley JJ, Bunn PA, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 2924–30

    PubMed  CAS  Google Scholar 

  118. LeBeau B, de la Salmoniere P, Ozenne G. alpha interferon as maintenance therapy for small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 475a

    Google Scholar 

  119. Ruotsalainen TM, Halme M, Tamminen K, et al. Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study. J Interferon Cytokine Res 1999; 19: 253–9

    Article  PubMed  CAS  Google Scholar 

  120. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994; 12: 2321–6

    PubMed  CAS  Google Scholar 

  121. Clamon G, Herndon J, Perry M, et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of cancer and leukemia group B. J Natl Cancer Inst 1993; 85: 316–20

    Article  PubMed  CAS  Google Scholar 

  122. Eisenhauer EA, O’Dwyer PJ, Christian M, et al. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18: 684–92

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Hoang is supported by grant K12-CA 87718. Dr Schiller is supported by grant CA 84172.

Author information

Authors and Affiliations

  1. Department of Medicine, Medical Oncology, University of Wisconsin, Madison, Wisconsin, USA

    Tien Hoang &  Joan H. Schiller

Authors
  1. Tien Hoang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan H. Schiller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan H. Schiller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoang, T., Schiller, J.H. Systemic Treatment of Small Cell Lung Cancer. Am J Cancer 1, 397–408 (2002). https://doi.org/10.2165/00024669-200201060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200201060-00003

Keywords

Search

Navigation